FOLLICULAR T-CELL LYMPHOMA
Clinical trials for FOLLICULAR T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for FOLLICULAR T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough lymphoma: experimental drug ST-001 enters human testing
Disease control Recruiting nowThis early-phase trial tests a new drug called ST-001 (a form of fenretinide) in people with T-cell non-Hodgkin lymphoma whose cancer has returned or not responded to prior treatments. The main goal is to find the safest dose and understand side effects. About 46 participants wil…
Matched conditions: FOLLICULAR T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: SciTech Development, Inc. • Aim: Disease control
Last updated May 26, 2026 04:51 UTC
-
New hope for tough lymphoma: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard single-agent treatments in 150 adults with certain types of T-cell lymphoma that have come back or not responded to prior therapy. The goal is to see if soquelitinib can delay cancer progression better than current …
Matched conditions: FOLLICULAR T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 04:33 UTC
-
Massive T-Cell lymphoma database aims to unlock better treatments
Knowledge-focused Recruiting nowThis study is creating a large database of information from 1,000 people with T-cell lymphoma. Researchers will collect medical records and tumor samples to learn more about the disease and how to improve care. No new treatments are being tested; the goal is to gather data for fu…
Matched conditions: FOLLICULAR T-CELL LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC